Cytostatic drug composition

Abstract

A drug composition containing as a drug substance a polymeric guanidine derivative based on a diamine containing oxyalkylene chains between two amino groups, with the guanidine derivative representing a product of polycondensation between a guanidine acid addition salt and a diamine containing polyalkylene chains between two amino groups, as well as the pharmaceutically acceptable salts thereof.

1 . A drug composition comprising as a drug substance a polymeric guanidine derivative based on a diamine containing oxyalkylene chains between two amino groups, with the guanidine derivative representing a product of polycondensation between a guanidine acid additional salt and a diamine containing polyalkylene chains between two amino groups, as well as the pharmaceutically acceptable salts thereof. 
     
     
         2 . A drug composition according to  claim 1 , wherein the diamine is selected from the group consisting of triethylene glycol diamine (relative molecular mass: 148), polyoxypropylene diamine (relative molecular mass: 230) and polyoxyethylene diamine (relative molecular mass: 600). 
     
     
         3 . A drug composition according to  claim 1 , wherein the drug substance is poly-[2-(2-ethoxyethoxyethyl)guanidinium hydrochloride] comprising at least 3 guanidinium groups. 
     
     
         4 . A drug composition according to  claim 2 , wherein the drug substance is poly-[2-(2-ethoxyethoxyethyl)guanidinium hydrochloride] comprising at least 3 guanidinium groups. 
     
     
         5 . A drug composition according to  claim 3 , wherein the average molecular mass of the drug substance ranges from 500 to 3000. 
     
     
         6 . A method of producing a cystostatic effect on a cancer cell, comprising administering, to the cancer cell, an effective amount of a drug substance selected from the group consisting of a polymeric guanidine derivative based on a diamine containing oxyalkylene chains between two amino groups, with the guanidine derivative representing a product of polycondensation between a guanidine acid addition salt and a diamine containing polyalkylene chains between two amino groups, and a pharmaceutically acceptable salt thereof. 
     
     
         7 . The method according to  claim 6 , wherein the diamine is selected from the group consisting of triethylene glycol diamine (relative molecular mass: 148), polyoxypropylene diamine (relative molecular mass: 230) and polyoxyethylene diamine (relative molecular mass: 600).